Object Details
- Genentech, Inc.
- Description (Brief)
- (From box) Dilute prior to use; for intravenous infusion only; single-use vial; discard unused portion
- (From insert)
- PERJETA is a HER2/neu receptor antagonist indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
- Location
- Currently not on view
- Credit Line
- Gift of Genentech, Inc.
- ca 2013
- product expiration date
- 2014-02
- ID Number
- 2013.0069.09
- catalog number
- 2013.0069.09
- accession number
- 2013.0069
- Object Name
- pharmaceutical
- biological
- Physical Description
- plastic (overall material)
- glass (overall material)
- metal (overall material)
- cardboard (overall material)
- pertuzumab, 420mg/14 mL (overall ingredient)
- Measurements
- overall: 1 3/4 in x 2 3/4 in x 3 1/8 in; 4.445 cm x 6.985 cm x 7.9375 cm
- overall: 3 in x 2 1/8 in x 2 1/8 in; 7.62 cm x 5.3975 cm x 5.3975 cm
- place made
- United States: California, South San Francisco
- See more items in
- Medicine and Science: Medicine
- Health & Medicine
- The Antibody Initiative
- Antibody Initiative: Monoclonal Antibodies
- National Museum of American History
- Subject
- Women's Health
- Record ID
- nmah_1445190
- GUID (Link to Original Record)
- https://n2t.net/ark:/65665/ng49ca746ad-d916-704b-e053-15f76fa0b4fa
.jpg)
